To evaluate the efiicacy of TAI combine SBRT in unresectable HCC
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
TREATMENT
Masking
NONE
Enrollment
33
TAI combine SBRT
SUN YAT-SEN University Cancer Center
Guangzhou, Guangdong, China
RECRUITINGPFS
progression-free survival
Time frame: From date of randomization until the date of progression, assessed up to 36 months
ORR
objective response rate
Time frame: From date of randomization until the date of death, assessed up to 36 months
OS
overall survival
Time frame: From date of randomization until the date of death from any cause, assessed up to 36 months
DCR
disease control rate
Time frame: From date of randomization until the date of death, assessed up to 36 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.